SEARCH

SEARCH BY CITATION

References

  • 1
    Freeman JA, Esrig D, Stein JP et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995; 76: 833839
  • 2
    Shariat SF, Palapattu GS, Karakiewicz PI et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51: 137149
  • 3
    Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2009; 9: 821830
  • 4
    Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int 2010; 106: 622
  • 5
    Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859866
  • 6
    International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999; 354: 533540
  • 7
    Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69: 6279
  • 8
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361: 19271934
  • 9
    Sonpavde G, Khan MM, Svatek RS et al. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int 2011; 108: 687692
  • 10
    Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 2008; 10: 3143
  • 11
    Quek ML, Stein JP, Nichols PW et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 2005; 174: 103106
  • 12
    Haleblian GE, Skinner EC, Dickinson MG, Lieskovsky G, Boyd SD, Skinner DG. Hydronephrosis as a prognostic indicator in bladder cancer patients. J Urol 1998; 160: 20112014
  • 13
    Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666675
  • 14
    Urinary bladder. In Greene FL , Page DL , Fleming ID et al. eds, AJCC Cancer Staging Manual, 6 edn. New York, NY: Springer-Verlag, 2002: 335340
  • 15
    Mostofi FK, Sobin HL, Torlini H. Histologic Typing of Urinary Bladder Tumors. Geneva: World Health Organization, 1973
  • 16
    Biggs D, de Ville B, Suen E. A method of choosing multiway partitions for classification and decision trees. J Appl Stat 1991; 18: 4962
  • 17
    Niegisch G, Albers P. Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer? Curr Opin Urol 2011; 21: 434439
  • 18
    Sturgeon SR, Hartge P, Silverman DT et al. Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology 1994; 5: 218225
  • 19
    Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 4665
  • 20
    Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24: 39673972
  • 21
    Vickers AJ, Cronin AM, Kattan MW et al. Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer 2009; 115: 54605469
  • 22
    Shariat SF, Karakiewicz PI, Palapattu GS et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006; 12: 66636676
  • 23
    Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol 2007; 51: 690697
  • 24
    Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24: 55525564
  • 25
    Nielsen ME, Shariat SF, Karakiewicz PI et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 2007; 51: 699706
  • 26
    Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 2006; 176: 493498
  • 27
    Cheng L, Neumann RM, Scherer BG et al. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. Cancer 1999; 85: 26382647
  • 28
    Boudreaux KJ Jr, Clark PE, Lowrance WT et al. Comparison of American Joint Committee on Cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol 2009; 181: 540545
  • 29
    Gakis G, Schilling D, Renninger M, Seibold J, Sievert KD, Stenzl A. Comparison of the new American Joint Committee on Cancer substratification in node-negative pT2 urothelial carcinoma of the bladder: analysis of patient outcomes in a contemporary series. BJU Int 2011; 107: 919923